The State of Biotech: Capital Markets, Industry Evolution & The Real Impact of AI

​Join BioSpark Group for an in-person event in San Francisco. Free on-site Parking. Ticket covers venue and dinner costs.

The biotech industry is navigating one of its most defining moments.

​After the exuberance of 2020–2021 and the prolonged capital winter that followed, the sector is entering a new phase — one shaped by capital discipline, strategic partnerships, platform differentiation, and the accelerating influence of AI.

​At this event, we will bring together founders, investors, scientists, and operators to discuss how fundraising is changing, where value is being created, and what AI actually means for company strategy.

​We will explore:

​🔹 How is biotech financing really evolving in 2026?

​🔹 What types of companies are still getting funded — and why?

​🔹 Are investors backing mechanisms, modalities, or teams?

​🔹 AI: hype cycle, infrastructure layer, or true value creator?

​🔹 How do startups balance scientific ambition with capital efficiency?

​🔹 What kind of companies will define the next biotech cycle?

​This discussion is designed for builders and decision-makers — founders raising capital, investors deploying it, and scientists shaping the next wave of innovation.

​BioSpark’s salon discussion series is intentionally small, selective, and interactive. We prioritize intellectual honesty, strategic depth, and cross-disciplinary dialogue. 

​If you care about where biotech capital is flowing, how company-building strategies are adapting, and what AI actually means for drug discovery and value creation, this will be a conversation worth joining.

​🎤 Meet Your Host: Dr. Avery Yan

​Dr. Yan is the Founder and CEO of Riboway Therapeutics, a Boston-based biotech leveraging AI to develop RNA-targeted therapeutics. She brings deep expertise across R&D, venture incubation, and business development, with contributions to over 20 drug programs and 5 IND filings. Previously, she led newco incubation and asset licensing at FUSION BioVenture and played a key role in launching Amgen’s innovative group in 2015, which pioneered the use of human iPSC/organoids and AI modeling for drug development. As the leader of BioSpark Group, Dr. Yan is dedicated to fostering thoughtful dialogue between academia, industry, and investment leaders on the frontiers of biotechnology.

​Seats are limited to maintain depth and quality of discussion.